Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Healthtrust
McKinsey
Mallinckrodt
Julphar
Dow
Cipla
US Department of Justice
Cantor Fitzgerald

Generated: August 17, 2018

DrugPatentWatch Database Preview

Allergan Inc Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN INC, and what generic alternatives to ALLERGAN INC drugs are available?

ALLERGAN INC has two approved drugs.

There are six US patents protecting ALLERGAN INC drugs.

There are twenty-five patent family members on ALLERGAN INC drugs in fifteen countries.

Summary for Allergan Inc
International Patents:25
US Patents:6
Tradenames:2
Ingredients:2
NDAs:2
Drug Master File Entries: 4
Patent Litigation for Allergan Inc: See patent lawsuits for Allergan Inc

Drugs and US Patents for Allergan Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Inc ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 RX Yes Yes 9,517,219 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes 8,420,688 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes 9,974,773 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes 8,883,838 ➤ Try a Free Trial Y ➤ Try a Free Trial
Allergan Inc ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Allergan Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Inc ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 5,863,560 ➤ Try a Free Trial
Allergan Inc ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 6,620,435 ➤ Try a Free Trial
Allergan Inc ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 6,060,085 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for ALLERGAN INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Gel 7.5% ➤ Subscribe 2017-02-13

Non-Orange Book US Patents for Allergan Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,017,231,985 ➤ Try a Free Trial
8,877,793 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists ➤ Try a Free Trial
8,815,929 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using .alpha..sub.1-adrenoceptor agonists ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Covington
Accenture
Cerilliant
Daiichi Sankyo
Federal Trade Commission
Fish and Richardson
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.